Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).

Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP.

J Thromb Haemost. 2010 Apr;8(4):714-21. doi: 10.1111/j.1538-7836.2010.03748.x. Epub 2010 Jan 17.

2.

Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.

Tran AH, Lee G.

Ann Pharmacother. 2003 Nov;37(11):1632-43. Review.

PMID:
14565815
3.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
4.

Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?

Strebel N, Prins M, Agnelli G, Büller HR.

Arch Intern Med. 2002 Jul 8;162(13):1451-6. Review.

PMID:
12090880
5.
6.
7.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

Turpie AG.

Surg Technol Int. 2004;13:261-7. Review.

PMID:
15744699
8.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
9.

Setting a standard for venous thromboembolism prophylaxis.

Turpie AG.

Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S18-23. Review.

PMID:
11715835
10.

Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.

Turpie AG.

Am Heart J. 2001 Aug;142(2 Suppl):S9-15. Review.

PMID:
11479485
11.
12.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Eriksson BI, Friedman RJ.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31. Review.

PMID:
19648146
13.

Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

Kwong LM.

Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6. Review.

14.

Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):201-2, 204. Review.

PMID:
23016247
15.

Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.

Imberti D, Prisco D.

Pathophysiol Haemost Thromb. 2008;36(5):217-26. doi: 10.1159/000252816. Epub 2009 Dec 9. Review.

PMID:
19996630
16.
17.

Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.

Yoshida Rde A, Yoshida WB, Maffei FH, El Dib R, Nunes R, Rollo HA.

Ann Vasc Surg. 2013 Apr;27(3):355-69. doi: 10.1016/j.avsg.2012.06.010. Epub 2013 Jan 23. Review.

PMID:
23351997
18.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
19.

Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GY.

Drugs. 2012 Sep 10;72(13):1755-64. doi: 10.2165/11635630-000000000-00000. Review.

PMID:
22876779
20.

Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.

Yong CM, Boyle AJ.

Curr Vasc Pharmacol. 2010 Jan;8(1):5-11. Review.

PMID:
19485937
Items per page

Supplemental Content

Write to the Help Desk